Status:
RECRUITING
Observation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project.
Lead Sponsor:
The First Affiliated Hospital of Zhengzhou University
Conditions:
Chronic Hepatitis b
Eligibility:
All Genders
18+ years
Brief Summary
This study is a multicenter, prospective, observational real-world study designed to investigate and analyze the current treatment patterns of chronic hepatitis B (CHB) across 200 hospitals in China. ...
Eligibility Criteria
Inclusion
- Chronic HBV infection (HBsAg-positive for ≥6 months); 2.Age ≥18 years; 3.Patients who, based on real-world clinical practice needs, are planned or currently receiving treatment with:Entecavir (ETV),Tenofovir disoproxil fumarate (TDF),Tenofovir alafenamide fumarate (TAF),Tenofovir amibufenamide (TMF) OR Pegylated interferon α-2b-naïve patients OR Patients re-initiating pegylated interferon α-2b therapy; 4.Written informed consent obtained from the patient.
Exclusion
- Severe hepatic dysfunction or decompensated cirrhosis; 2.Concurrent participation in other clinical trials; 3.Hepatocellular carcinoma (HCC).
Key Trial Info
Start Date :
June 3 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2032
Estimated Enrollment :
15000 Patients enrolled
Trial Details
Trial ID
NCT07169656
Start Date
June 3 2024
End Date
December 31 2032
Last Update
September 12 2025
Active Locations (162)
Enter a location and click search to find clinical trials sorted by distance.
1
Huaxian People's Hospital
Anyang, China
2
Linzhou City People's Hospital
Anyang, China
3
Neihuang County People's Hospital
Anyang, China
4
Tangyin County People's Hospital
Anyang, China